Detalhe da pesquisa
1.
Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.
N Engl J Med
; 387(12): 1099-1110, 2022 09 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36129998
2.
Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.
N Engl J Med
; 383(2): 109-119, 2020 07 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32640130
3.
Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial.
Mult Scler
; 22(2): 212-21, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25921050
4.
Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine.
CNS Drugs
; 33(1): 61-79, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30535670
5.
Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: Item-level analysis of the MSIS-29.
J Neurol Sci
; 370: 123-131, 2016 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27772740
6.
Identifying an important change estimate for the Multiple Sclerosis Walking Scale-12 (MSWS-12v1) for interpreting clinical trial results.
Mult Scler J Exp Transl Clin
; 1: 2055217315596993, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-28607701
7.
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.
Lancet Neurol
; 13(5): 472-81, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24656609